SK Biopharma gets KDDF investment grant to develop novel oncology candidate, SKL27969

SK Biopharmaceuticals, a global innovative pharmaceutical company, announced that the state-run Korea Drug Development Fund (KDDF) has decided to support and finance the company's development of SKL27969, which is being evaluated as potential treatment for patients with advanced solid tumours, widening SK Biopharmaceuticals' area into oncology. The KDDF is a government fund that aims to support R&D for new drug development as part of efforts to advance Korea's pharmaceuticals and biotechnology sectors. A phase 1/2 clinical trial is being conducted under the US IND for SKL27969, a PRMT5 inhibitor, in adult patients with solid tumours for safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy.

SK Biopharmaceuticals said the KDDF's two-year investment in the study will help the company and its US subsidiary SK Life Science, Inc. to accelerate their clinical (phase 1) and nonclinical trials, while expanding its oncology network. SK Biopharmaceuticals will present its preclinical data of SKL27969 at the annual Society for Neuro-Oncology (SNO) conference in Tampa Bay, Florida, November 16 - 20, 2022. SKL27969 is a protein arginine methyltransferase 5 (PRMT5) inhibitor candidate that has shown activity in preclinical models of solid tumours, such as glioblastoma (GBM), non-small cell lung cancer (NSCLC), and triple negative breast cancer (TNBC).

SK Biopharmaceuticals and its US subsidiary SK life science are pharmaceutical companies focused on the global research, development and commercialization of treatments for disorders of the central nervous system (CNS) and oncology.